October 1, 2025

Jupiter Neurosciences, Inc (NASDAQ:JUNS)

‍

GTM Strategic Advisory

Jupiter Neurosciences, Inc. (NASDAQ:JUNS) is a clinical-stage pharmaceutical company advancing therapies for neuro-inflammation central nervous system disorders, while expanding into consumer health with the launch of Nugevia™.

As they prepared for this launch, JUNS faced unexpected roadblocks that affected timing and continuity.

By utilizing a few of our banking partners, Jupiter cleared obstacles and advanced their launch with speed and white-glove execution.

‍

Below are photos they personally shared of a successful launch.

‍

About JUNS

Headquartered in Jupiter, Florida, Jupiter Neurosciences is developing therapies targeting conditions including Parkinson’s disease, Alzheimer’s, and rare neuro-inflammatory disorders.

In 2025, the company broadened its strategy with the launch of Nugevia™, a nutraceutical line powered by its patented JOTROL™ technology, clinically shown to increase resveratrol bioavailability by up to nine-fold. The first products: GLO, PWR, and MND, target skin vitality, mitochondrial performance, and cognitive resilience. With this expansion, Jupiter is positioned to capture growth in the multi-trillion-dollar longevity and wellness market.